Labuxtinib

CAS No. 1426449-01-5

Labuxtinib( —— )

Catalog No. M37250 CAS No. 1426449-01-5

Labutinib is a selective inhibitor of the c-kit tyrosine kinase .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 373 In Stock
5MG 337 In Stock
10MG 541 In Stock
25MG 1074 In Stock
50MG 1516 In Stock
100MG 2037 In Stock
200MG 2744 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Labuxtinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Labutinib is a selective inhibitor of the c-kit tyrosine kinase .
  • Description
    Labuxtinib is c-kit tyrosine kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR | c-Kit
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1426449-01-5
  • Formula Weight
    377.37
  • Molecular Formula
    C20H16FN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (331.24 mM; Ultrasonic )
  • SMILES
    C(NC1=CC(=CC=C1C)C=2N=C(ON2)[C@@H]3[C@@H](F)C3)(=O)C=4N5C(=NC4)C=CC=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yeh Vince, et al. Imidazopyridine compounds and compositions as c-kit kinase inhibitors and their preparation. World Intellectual Property Organization, WO2013033070 A1. 2013-03-07.
molnova catalog
related products
  • Pyrotinib maleate

    Pyrotinib maleate (SHR-1258 maleate)?is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM.

  • AG-825

    AG-825(Tyrphostin C15) is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.